Andean Precious Metals Corp (ANPMF)

Angiotech Pharmaceuticals Inc is a pharmaceutical and medical device company that develops, manufactures and markets medical device products and technologies, primarily within the areas of interventional oncology, wound closure and ophthalmology. The Company currently operates in two segments: Medical Device Technologies and Licensed Technologies. Its Medical Device Technologies segment generates the majority of its revenue, develops, manufactures and markets a wide range of single use medical device products, as well as precision manufactured medical device components. These products and components are sold directly to hospitals, clinics, physicians and other end users, as well as to medical products distributors or other third-party medical device manufacturers. Its Licensed Technologies segment includes certain of its legacy technologies for which research and development activities have been concluded. This segment generates additional revenue in the form of royalties received from partners who have licensed and utilize these technologies in their medical device product lines. The Medical Device Technologies segment manufactures and markets single-use specialty medical device products and medical device components. These products are sold directly to end users or other third-party medical device manufacturers. This segment contains significant manufacturing capabilities as well as specialized direct and indirect sales and distribution capabilities. Many of its medical products are made using proprietary manufacturing processes and may be protected by its patent portfolio or proprietary know-how. Its significant product groups within this business segment include Interventional Oncology, Wound Closure, Ophthalmology and Medical Device Components. The Licensed Technologies segment includes certain of its legacy technologies for which research and development activities have been concluded. This segment generates additional revenue in the form of royalties received from partners who have licensed and utilize these technologies in their medical device product lines. Its principal revenues in this segment to date have been royalties derived from sales by its partner BSC of TAXUS paclitaxel-eluting coronary stents for the treatment of coronary artery disease. The Company markets and sells various medical device products through a group of specialized sales organizations that consist of direct sales and marketing personnel, which in some cases are supplemented by independent sales representatives and independent medical products distributors, depending on the product category, customer base or geographic location. The research and development, manufacturing, labeling, advertising, sale, marketing and third-party reimbursement of its medical device products and those of the Company's suppliers, customers and partners are subject to extensive regulation by the FDA, the U.S. Department of Health and Human Services Centers for Medicare